Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma.

We report a patient with hepatosplenic T-cell lymphoma (HSTL) and compare the disease to the derived xenograft model. Enhancer of zeste homolog 2 (EZH2) inhibitor treatment of an EZH2-mutant HSTL patient-derived xenograft model led to prolonged survival.

[1]  Joshua M. Dempster,et al.  Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models , 2018, Nature Communications.

[2]  T. Owa,et al.  Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. , 2018, The Lancet. Oncology.

[3]  W. Béguelin,et al.  Enhancer of zeste homolog 2 (EZH2) inhibitors , 2018, Leukemia & lymphoma.

[4]  I. Feldman,et al.  EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL , 2017, Molecular Cancer Therapeutics.

[5]  D. Dunson,et al.  The Genetic Basis of Hepatosplenic T-cell Lymphoma. , 2017, Cancer discovery.

[6]  J. Aster,et al.  Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies. , 2016, The Journal of molecular diagnostics : JMD.

[7]  K. Stegmaier,et al.  Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia , 2015, Clinical Cancer Research.

[8]  Tim J. Wigle,et al.  Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma , 2014, Molecular Cancer Therapeutics.

[9]  L. Staudt,et al.  EZH2 mutations are frequent and represent an early event in follicular lymphoma. , 2013, Blood.

[10]  Tim J. Wigle,et al.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. , 2012, Nature chemical biology.

[11]  P. Gaulard,et al.  Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. , 2012, Blood.

[12]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[13]  Ryan D. Morin,et al.  Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. , 2011, Blood.

[14]  R. Copeland,et al.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas , 2010, Proceedings of the National Academy of Sciences.

[15]  Ryan D. Morin,et al.  Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.

[16]  P. Gaulard,et al.  Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients , 2003 .

[17]  S. Stass,et al.  Isochromosome 7q: the primary cytogenetic abnormality in hepatosplenic γδ T cell lymphoma , 1997, Leukemia.